Remimazolam and Ciprofol: More Research Is Needed but Ask the Right Questions and Perhaps Aim Higher

Editorial| December 2024 Remimazolam and Ciprofol: More Research Is Needed but Ask the Right Questions and Perhaps Aim Higher J. Robert Sneyd, M.D., Ph.D.; J. Robert Sneyd, M.D., Ph.D. 1Faculty of Medicine and Dentistry, University of Plymouth, Plymouth, United Kingdom. Search for other works by this author on: This Site PubMed Google Scholar Brian J. Anderson, M.B., Ch.B., Ph.D. Brian J. Anderson, M.B., Ch.B., Ph.D. 2Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. https://orcid.org/0000-0002-2826-3019 Search for other works by this author on: This Site PubMed Google Scholar Author and Article Information Accepted for publication August 8, 2024. Address correspondence to Dr. Sneyd: Anesthesiology December 2024, Vol. 141, 1034–1038. https://doi.org/10.1097/ALN.0000000000005195 Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Cite Icon Cite Get Permissions Search Site Citation J. Robert Sneyd, Brian J. Anderson; Remimazolam and Ciprofol: More Research Is Needed but Ask the Right Questions and Perhaps Aim Higher. Anesthesiology 2024; 141:1034–1038 doi: https://doi.org/10.1097/ALN.0000000000005195 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll PublicationsAnesthesiology Search Advanced Search Topics: remimazolam City dwellers of a certain age will recall lengthy waits for a bus followed eventually by the arrival of three on the same route driving nose-to-tail. So it is with intravenous hypnotics. Since the discovery of propofol, it has been a long wait. Now we have remimazolam (two different versions) launched worldwide, ciprofol in phase 3 studies, and several other candidates in the early stages of development. The editorial offices of scientific journals receive news of these projects as papers, letters, and abstracts; these take their chances with peer review and editorial sentiment. Growth in the pace and breadth of the publishing process has been matched by a progressive increase in submissions of original research and particularly of reviews (fig. 1). Asian investigators now dominate the field. Of 734 publications concerning remimazolam since 2010, 73% came from China, Japan, or South Korea. Since 2022 the proportion has increased... You do not currently have access to this content.